Related Experiment Video

Updated: Jul 27, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Growth factors and their receptors: new targets for prostate cancer therapy

J Barton1, G Blackledge, A Wakeling

  • 1AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom.

Urology
|August 15, 2001
PubMed

Insights

Targeting the epidermal growth-factor receptor (EGFR) pathway shows promise for cancer treatment. Therapies like monoclonal antibodies and small-molecule inhibitors are advancing in clinical trials, with some showing encouraging results for prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The epidermal growth-factor receptor (EGFR) pathway is crucial for tumor cell proliferation, survival, and metastasis.
  • Dysregulation of EGFR signaling is implicated in various cancers, including prostate cancer.

Purpose of the Study:

  • To review current therapeutic strategies targeting the EGFR signaling pathway.
  • To highlight the clinical development of agents aimed at inhibiting EGFR in cancer treatment.

Main Methods:

  • Review of therapeutic approaches including monoclonal antibodies, immunotoxin conjugates, antisense strategies, and small-molecule tyrosine kinase inhibitors.
  • Summary of agents in clinical and preclinical development, such as cetuximab, trastuzumab, and ZD1839.

Main Results:

  • Monoclonal antibodies and immunotoxins targeting EGFR are in clinical trials for various cancers.
  • Small-molecule EGFR tyrosine kinase inhibitors, including ZD1839, are in clinical development.
  • ZD1839 has demonstrated encouraging results in early-phase trials for prostate cancer patients.

Conclusions:

  • Targeting the EGFR pathway represents a significant therapeutic strategy in oncology.
  • Multiple drug classes are being investigated, showing potential for treating EGFR-driven cancers.
  • Further clinical evaluation is warranted for these novel therapeutic agents.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: